First reported by Project CBD in July of this year, scientists at the University of Louisville School of Medicine in Kentucky have identified an unknown molecular target of CBD that could have significant therapeutic implications for Parkinson’s Disease. CBD activates a g-coupled protein receptor called GPR6. A depletion of this receptor causes an increase of dopamine in the brain. Acting as an inverse agonist at the GPR6 receptor, CBD boosts dopamine levels in preclinical trials.
Researchers believe in the 1:1 ratio (cbd:thc) to help Parkinson’s patients.
follow us on Twitter @bchsidemed
